Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.80 |
| ▸ | PI4KA | P42356 | 2/20 | 0.80 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.80 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.80 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.80 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.80 |
| ▸ | GAPDH | P04406 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.80 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10584336-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10093926-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10072265-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-6531584-B1 | Nuclease resistant oligonucleotide analogs; DNA or RNA modulation; diagnosis, thearpy of viral diseases | ISIS PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6399754-B1 | CONTAINING SULFOPHOSPHATE GROUP | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6262241-B1 | ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES | ISIS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-6194598-B1 | Aminooxy-modified oligonucleotide synthetic intermediates | ISIS PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6005087-A | NUCLEASE RESISTANT OLIGONUCLEOTIDES WHICH ARE USEFUL AS THERAPEUTICS, DIAGNOSTICS, AND RESEARCH REAGENTS FOR VARIOUS VIRAL DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859221-A | HYBRID DNA, RNA; NUCLEASE RESISTANT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5670633-A | TREATMENT AND DIAGNOSIS OF DISEASES AMENABLE TO MODULATION OF THE PRODUCTION OF SELECTED PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | ADORA3 1706/4885ADORA1 2222/4885ADORA2A 1120/4885 |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | ADORA3 3719/4885ADORA1 4428/4885ADORA2A 3599/4885 |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | ADORA3 3719/4885ADORA1 4428/4885ADORA2A 3599/4885 |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | NSUN2, SNRPE, RBM3 | ADORA3 3732/4885ADORA1 4432/4885ADORA2A 3608/4885 |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | ADORA3 1615/4885ADORA1 2142/4885ADORA2A 1066/4885 |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | ADORA3 3719/4885ADORA1 4428/4885ADORA2A 3599/4885 |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | ADORA3 3719/4885ADORA1 4428/4885ADORA2A 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.